King's Health Partners Confidence in Concept

Lead Research Organisation: King's College London

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Technical Summary

The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding.  It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.

Publications

10 25 50

publication icon
Blest-Hopley G (2018) Residual effects of cannabis use in adolescent and adult brains - A meta-analysis of fMRI studies. in Neuroscience and biobehavioral reviews

 
Description Appointment as Policy Officer to the Genetics Society
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
URL http://www.genetics.org.uk/mission-and-priorities/committee-members/
 
Description Biomarker discovery in pheochromocytomas and paragangliomas to identify disease severity and progression
Amount £21,000 (GBP)
Organisation Bernice Bibby Research Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2021 
End 12/2023
 
Description Biomarker discovery in pheochromocytomas and paragangliomas to identify disease severity and progression
Amount £20,000 (GBP)
Organisation Bernice Bibby Research Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 11/2018 
End 11/2021
 
Description Biotherapeutics Drug Discovery project
Amount £224,404 (GBP)
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 05/2016 
End 11/2018
 
Description CONACYT (mexican government) fully funded PhD studentship
Amount £45,000 (GBP)
Organisation National Council on Science and Technology (CONACYT) 
Sector Public
Country Mexico
Start 10/2016 
End 10/2019
 
Description Cellular and sub-cellular sampling using laser capture microdissection to understand disease mechanisms
Amount £352,000 (GBP)
Funding ID 212917/Z/18/Z 
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2019 
End 10/2022
 
Description Confidence in Collaboration in Advanced Therapies Award
Amount £99,151 (GBP)
Organisation United Kingdom Research and Innovation 
Department Research England
Sector Public
Country United Kingdom
Start 01/2020 
End 06/2021
 
Description Crick-KCL PhD studentship (Joint program)
Amount £50,000 (GBP)
Organisation King's College London 
Sector Academic/University
Country United Kingdom
Start 10/2017 
End 09/2021
 
Description Developing advanced CAR-T cell-based immunotherapies to improve the outcome of patients with pancreatic cancer
Amount £1,000,000 (GBP)
Funding ID 2017GrandChallengeAward 
Organisation Pancreatic Cancer UK 
Sector Charity/Non Profit
Country United Kingdom
Start 07/2017 
End 07/2020
 
Description Drug Discovery Committee - Biotherapeutics Drug Discovery Project Award
Amount £69,477 (GBP)
Funding ID C11499/A21623 
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 06/2016 
End 08/2019
 
Description Efficacy and Mechanism Evaluation scheme- currently at the contracting stage with NIHR; so final grant amount subject to adjustment.
Amount £1,765,128 (GBP)
Organisation NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC) 
Sector Public
Country United Kingdom
Start 08/2018 
End 04/2023
 
Description Engineering avb6-targeted fourth generation chimeric antigen receptor (CAR) T-cells for immunotherapy of pancreatic ductal adenocarcinoma
Amount £224,403 (GBP)
Funding ID 21623 
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 07/2016 
End 01/2020
 
Description European Haematological Society
Amount € 12,000 (EUR)
Organisation European Hematology Association (EHA) 
Sector Charity/Non Profit
Country Netherlands
Start 10/2017 
End 02/2018
 
Description GE Healthcare Studentship
Amount £48,000 (GBP)
Organisation GE Healthcare Limited 
Sector Academic/University
Country United Kingdom
Start  
 
Description Genetic analysis to identify biomarkers in pheochromocytoma and paraganglioma
Amount £10,000 (GBP)
Organisation Kings BRC 
Sector Academic/University
Country United Kingdom
Start 09/2017 
End 04/2018
 
Description Graduate Teaching Assistant (GTA) PhD studentship
Amount £40,114 (GBP)
Organisation King's College London 
Sector Academic/University
Country United Kingdom
Start 10/2015 
End 09/2019
 
Description Identification of therapeutic targets in patients with myeloproliferative neoplasms
Amount £10,000 (GBP)
Organisation King's College London 
Sector Academic/University
Country United Kingdom
Start 12/2018 
End 12/2019
 
Description Identifying hypoxia-mediated effects on breast cancer invasion in vivo.
Amount £26,860 (GBP)
Organisation Breast Cancer Now 
Sector Charity/Non Profit
Country United Kingdom
Start 05/2016 
End 04/2017
 
Description Integrating Imaging into Immunotherapy - Developing PET traceable CAR T-cells.
Amount £170,479 (GBP)
Funding ID 16-1135 
Organisation Worldwide Cancer Research 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2016 
End 08/2018
 
Description Integrating medical imaging into cancer immunotherapy: Development of clinically traceable CAR and GammaDelta T-cells
Amount £501,608 (GBP)
Funding ID A21153 
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 07/2016 
End 06/2019
 
Description KHP Challenge Fund
Amount £54,064 (GBP)
Organisation King's College London 
Sector Academic/University
Country United Kingdom
Start 09/2020 
End 08/2021
 
Description King's College London CDT in Chemistry for a Healthy and Sustainable Society
Amount £78,000 (GBP)
Organisation King's College London 
Sector Academic/University
Country United Kingdom
Start 02/2021 
End 01/2025
 
Description King's Health Partners Confidence in Concept - MC_PC_14105 'Identification of rare variants that predispose to lobular breast carcinoma'
Amount £50,000 (GBP)
Funding ID King's Health Partners Confidence in Concept - MC_PC_14105 'Identification of rare variants that predispose to lobular breast carcinoma' 
Organisation King’s Health Partners 
Sector Academic/University
Country United Kingdom
Start 07/2015 
End 06/2016
 
Description LiDo BBSRC DTP rotation student
Amount £6,000 (GBP)
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 10/2019 
End 07/2020
 
Description London Medical Imaging & Artificial Intelligence Centre for Value-Based Healthcare
Amount £9,985,272 (GBP)
Funding ID 104691 
Organisation Innovate UK 
Sector Public
Country United Kingdom
Start 02/2019 
End 01/2022
 
Description MRC Clinical research training Fellowship to Dr Musa Sami (PhD student)
Amount £246,419 (GBP)
Funding ID MR/P001408/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 08/2016 
End 07/2019
 
Description MRC Discovery Award
Amount £1,000,000 (GBP)
Funding ID MC_PC_15068 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 04/2016 
 
Description Molecular Genetics of Lobular Breast Cancer in a South African cohort and effect of HIV infection.
Amount £202,436 (GBP)
Funding ID MR/S014268/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 11/2018 
End 11/2020
 
Description Multidisciplinary Project Award Application Title: Integrating medical imaging into cancer immunotherapy: Development of clinically traceable CAR and GammaDelta T-cells
Amount £501,608 (GBP)
Funding ID C48390/A21153 
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2016 
End 12/2018
 
Description Predicting metastatic potential in PPGL syndrome patients
Amount £10,000 (GBP)
Organisation Association for Multiple Endocrine Neoplasia Disorders 
Sector Charity/Non Profit
Country United Kingdom
Start 04/2021 
End 03/2022
 
Description Prevent Ductal Carcinoma in Situ Invasive Overtreatment Now - PRECISION
Amount £3,542,559 (GBP)
Funding ID 25272 
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 05/2017 
End 04/2022
 
Description Prevention of chronic respiratory morbidity following premature birth
Amount £62,299 (GBP)
Organisation King's College London 
Department Kings Health Partners Challenge Fund
Sector Academic/University
Country United Kingdom
Start  
 
Description Response Mode Project Grant
Amount £576,418 (GBP)
Funding ID MR/R008264/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 05/2018 
End 04/2021
 
Description SRA with GammDelta Therapeutics
Amount £762,000 (GBP)
Organisation GammaDelta Therapeutics Ltd 
Sector Private
Country United Kingdom
Start 08/2016 
End 08/2018
 
Description TAP
Amount £239,000 (GBP)
Funding ID 2014NovTAP379 
Organisation Breast Cancer Campaign (BCC) 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2016 
End 12/2019
 
Description Targeting senescence to prevent, alleviate or delay multiple chronic age-related diseases
Amount £100,000 (GBP)
Organisation King's College London 
Sector Academic/University
Country United Kingdom
Start 01/2020 
End 12/2021
 
Description The Resilient Brain. Imaging Biomarkers of Brain Metabolic Reserve
Amount £452,468 (GBP)
Funding ID BB/N009088/1 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 12/2016 
End 11/2019
 
Description The Resilient Brain. Imaging Biomarkers of Brain Metabolic Reserve
Amount £452,468 (GBP)
Funding ID BB/N009088/1 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 12/2016 
End 11/2019
 
Description The relation of cerebral oxygen delivery to brain dysmaturation and damage in infants with congenital heart disease
Amount £211,718 (GBP)
Funding ID FS/15/55/31649 
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2015 
End 09/2018
 
Description Translational award (Thymus derived Tregs expanded in vitro as a treatment for paediatric heart transplant patients to prevent cardiac allograft vasculopathy)
Amount £230,158 (GBP)
Funding ID TG/16/2/32657 
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2017 
End 12/2018
 
Description Using multi-omic data for neuroendocrine cancer diagnostics and metastatic predictions
Amount £55,000 (GBP)
Organisation GlaxoSmithKline (GSK) 
Sector Private
Country Global
Start 10/2020 
End 04/2024
 
Description Wellcome EPSRC Centre for Medical Engineering
Amount £6,165,151 (GBP)
Funding ID NS/A000049/1 
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Public
Country United Kingdom
Start 04/2017 
End 04/2022
 
Title CRISPR knock out human fibroblast cell lines 
Description We have established CRISPR plasmids to allow us to knock out specific genes or interest in human fibroblast cell lines. We have identified specific cross talk between human dermal fibroblasts and tissue resident gamma delta T cells. We undertook several experiments ruling out classic checkpoint control molecules such as B7 like molecules, CTLA4, LAG3, TIM3 for which staining and blocking reagents are available. As none of these candidates showed any influence on gamma delta T cell biology, we required CRISPR technology to knock out specific proteins of interest, such as newly emerging immunosuppressive molecules such as TIGIT-PVR. To date we have established CRISPR and applied it to generate 3 different human fibroblast knock out lines which we are currently testing in co cultures with stimulated human tissue derived gamma delta T cells. 
Type Of Material Cell line 
Provided To Others? No  
Impact As counterparts for human gamma delta T cells do not directly exist in mice we need strong ex-vivo/in vitro assays to study gamma delta T cell behaviour closely resembling the in-situ situation. We have previously established a co culture of human fibroblast lines and tissue derived gamma delta T cells showing that in direct contact with dermal fibroblasts, gamma delta T cells remain inactive and display a similar phenotype to those directly isolated from tissue. With the use of CRISPR we can now manipulate single proteins, hopefully identifying molecules involved in tissue homoeostasis and checkpoint control inhibition that are not yet known with possible direct implications for translational science and immunotherapy. 
 
Title Enhanced cytokine mediated gamma delta T cell expansion 
Description We have previously identified mechanisms of tissue damage and dissociation which cause downstream activation of tissue resident gamma delta T cells. This allows for the first time for the isolation and expansion of human tissue resident gamma delta T cells. As part of this grant proposal we aimed to optimise the expansion of gamma delta T cells by testing 20 different chemokines, cytokines and growth factors to support and co stimulate gamma delta T cell expansion. Whilst extensive testing is still undergoing we have identified two candidate cytokines so far which support gamma delta T cell growth specifically, allowing for even greater expansion of these cells than we initially achieved with the support of IL-2 only. We are confident that via additional combinations of additional cytokines we can boost this effect even further reaching large scale expansion suitable for clinical application. Currently we are able to expand up to 10 to the 8 tissue derived gamma delta T cells per donor. Once the ideal cocktail has been identified, we aim to test these conditions in growth media supplemented with human serum, and ideally in serum free conditions, in appropriate culture systems, preparing the ground for GMP concordant expansion of tissue derive gamma delta T cells. 
Type Of Material Technology assay or reagent 
Provided To Others? No  
Impact There is great interest from research groups and industry to use human gamma delta T cells for adaptive immunotherapy as well as CAR T cell technology. Our newly developed and optimised protocols allow, for the first time, the expansion of tissue derived gamma delta T cells to clinically relevant numbers. This in vitro expansion system will also allow us to further explore the biology of these cells enabling us to identify ligands for these unconventional T cells - which are MHC unrestricted and do not recognise peptide antigens. This will generate vast interest in the immunological research community, and may ultimately lead to the development of a novel tissue derived gamma delta T cell check point therapy. 
 
Title Isolation and identification of fibroblast derived gamma delta interacting proteins 
Description Method 1: By isolating cell surface proteins from HFF cells and performing an IP using whole primary gamma delta 1 T cells, before performing a series of elutions, we will isolate proteins which interact with gamma deltas in a physiologically relevant manner. These proteins will then be sent for mass spec. analysis. The resulting qualitative and quantitative data will inform our choice of check point candidate. Method 2: By crosslinking and isolating the cell surface proteome of gamma delta 1 T cells we will IP the CD3 TCR complex using an anti CD3zeta antibody. This will be used as a probe to futher IP the interacting protein from the HFF cell surface proteome isolate. The protein of interest will be sent for mass spec. analysis, with the resulting data informing us of the TCR interacting protein(s). 
Type Of Material Biological samples 
Provided To Others? No  
Impact One of the aims of this work is to to identify a novel checkpoint for gamma delta 1s. The observation that the interaction between delta 1 s and fibroblasts inhibits expansion / activation suggests such a checkpoint exists in this system. Inhibition of this 'de-activation' may be beneficial for anti-cancer immunotherapeutic techniques involving these cells, in a similar manner to PD1 or CTLA4. 
 
Title Purification and Expansion of Explanted thymic T-regs 
Description We have already obtained thymic tissues taken from two children undergoing cardiac surgery. We have characterised the T cell composition of these samples and have purified Tregs by fluorescence activated cell sorting using established strategies applied to peripheral blood Tregs (CD4, CD25 and CD127). Thymic Tregs were then expanded polyclonally. Additionally, sorted Treg populations have also been preserved to analyse TSDR methylation status (a measure of FOXP3 stability) and TCR diversity using RNAseq approaches. 
Type Of Material Cell line 
Year Produced 2015 
Provided To Others? Yes  
Impact Development of a potential clinical application for heart transplantation. 
 
Title Viral CAR::Reporter plasmid for preclinical dual-mode in vivo imaging 
Description A new plasmid DNA was created to enable virus-mediated genetic engineering of primary human T-cells to express a chimeric antigen receptor together with a radionuclide-fluorescence dual-mode reporter gene; the latter is intended for in vivo tracking of engineered cellular therapeutics (in preclinical models) 
Type Of Material Technology assay or reagent 
Provided To Others? No  
Impact This tool enables in vivo cell tracking of all CAR T-cell therapeutics by radionuclide-fluorescence imaging in preclinical in vivo models. It contributes to the development of such therapeutics. 
 
Description Bayer 
Organisation Bayer
Department Bayer HealthCare
Country Germany 
Sector Private 
PI Contribution We are working with Bayer HC to develop adoptive immunotherapeutic strategies for triple negative breast cancer using ex-vivo expanded gamma delta T-cells.
Collaborator Contribution Bayer HC have provided know how and input into several aspects of the project, notably microarray analysis of expanded cells.
Impact Grant funding has been achieved.
Start Year 2015
 
Description Co-Sponsor, Wellcome Trust. Clinical Research Career Development Fellowship to Sasha Howard "Disorders of human pubertal timing". 
Organisation Queen Mary University of London
Department William Harvey Research Institute
Country United Kingdom 
Sector Academic/University 
PI Contribution I co-sponsored this clinical fellow by providing expertise in epigenetics and epigenomics and helped her write this part of her fellowship which was successfully funded in 2020.
Collaborator Contribution The partner is the lead PI and clinical fellow who generated the preliminary data and designed the project to which I contributed.
Impact Funded fellowship will start April 2021.
Start Year 2020
 
Description Collaboration with Accretion biotechnology Ltd 
Organisation Accretion Biotechnology Ltd
Country United Kingdom 
Sector Private 
PI Contribution We are in the process of collecting data to provide information on whether the tracer can be used to evaluate response of prostate cancer to chemotherapy in a mouse model. It is hoped that this will provide pre-clinical data for a clinical trial which will facilitate marketing of the tracer for clinical use for response to therapy. Additionally, Prof. Philip Blower (Co-investigator) is the primary supervisor of the PhD student supported by the collaborator. The research team have demonstrated that the tracer accumulates specifically in PSMA positive prostate cancer xenografts.
Collaborator Contribution Accretion Biotechnology have licensed the KCL Patent for 68Ga-CP256-PSMA in return for providing a Gallium generator, funding a PhD student, milestone payments and building a commercial network to facilitate product development, manufacture and marketing of the tracer.
Impact The collaboration is multidisciplinary: KCL provides: Biologist, chemists, clinical scientists Accretion Biotechnology provide: Business development
Start Year 2015
 
Description Collaboration with AstraZeneca 
Organisation AstraZeneca
Country United Kingdom 
Sector Private 
PI Contribution Expertise and intellectual input on novel imaging methods to develop and evaluate the novel nanoparticle-based drug delivery systems developed by the company
Collaborator Contribution In kind contribution of novel drug delivery systems and nanomedicines, expertise and intellectual inpout on these systems, access to facilities
Impact None yet
Start Year 2020
 
Description Collaboration with AstraZeneca 
Organisation AstraZeneca
Country United Kingdom 
Sector Private 
PI Contribution Expertise and intellectual input on novel imaging methods to develop and evaluate the novel nanoparticle-based drug delivery systems developed by the company
Collaborator Contribution In kind contribution of novel drug delivery systems and nanomedicines, expertise and intellectual inpout on these systems, access to facilities
Impact None yet
Start Year 2020
 
Description Collaboration with NBRC, India 
Organisation National Brain Research Centre, India
Country India 
Sector Public 
PI Contribution Applied for funding to host a postdoctoral fellow funded by the Newton International fellowship scheme of the Academy of Medical Sciences, UK.
Collaborator Contribution Contributed to the funding application and identified the postdoctoral fellow.
Impact No outputs yet
Start Year 2015
 
Description Exploiting cancer-specific perturbations of the chromatin complex network leading to dependencies and vulnerabilities that are actionable in therapy 
Organisation Francis Crick Institute
Country United Kingdom 
Sector Academic/University 
PI Contribution Joint PhD student between Francesca Ciccarelli's group at the Crick and my group. My group provides the epigenetics component of the project and wet lab provision.
Collaborator Contribution Francesca Ciccarelli's group steers the computational supervision of the PhD student and cancer biology training.
Impact Multi-disciplinary between epigenomics and bioinformatics. New collaboration, no outputs yet.
Start Year 2017
 
Description GSK funded PhD studentship in partnership with the GSTT-BRC 
Organisation GlaxoSmithKline (GSK)
Country Global 
Sector Private 
PI Contribution Preliminary data from my research group was presented as a project in the DRIVE-Health CDT and GSK showed interest in it and funded half a PhD studentship for 3.45 years.
Collaborator Contribution My collaborators Cynthia Andoniadou and Louise Izatt made intellectual contributions to the formation of the PhD project design
Impact Funded PhD studentship began October 2020.
Start Year 2020
 
Description Jak2V617F Mice 
Organisation Harvard University
Country United States 
Sector Academic/University 
PI Contribution PhD student undertook a 3 month laboratory stay in Boston at Harvard University to study the effect of hydroxycarbamide on DNA methylation and gene expression to match the human study undertaken at KCL. The subsequent data analysis was performed at KCL.
Collaborator Contribution Dr Ann Mullally provided a 3-month research placement for a PhD student plus access to the Jak2V617F mouse model which is a model for the human disorders essential thrombocythemia and polycythemia vera.
Impact The effect of hydroxycarbamide treatment on DNA methylation and gene expression in essential thrombocythemia and polycythemia vera: a cross-species study Stephania Contreras-Castillo1, Bertille Montibus1, Azucena Rocha2, Will Duke2, Ferdinand von Meyenn1,a, Donal McLornan3, Claire Harrison3, Ann Mullally2, Reiner Schulz1 & Rebecca J. Oakey1*. Submitted to Blood 2020.
Start Year 2018
 
Description Paradifference Foundation: Project grant. PI: C Andoniadou, Co-I: R Oakey. 
Organisation King's College London
Department Dental Institute
Country United Kingdom 
Sector Academic/University 
PI Contribution I co-designed and co-wrote an application to the Paradifference Foundation using preliminary data from my lab and the grant was funded
Collaborator Contribution Cynthia Andoniadou co-designed and co-wrote the application to the Paradifference Foundation using preliminary data from her lab and the grant was funded £450000
Impact Funded grant will begin in Summer 2021.
Start Year 2019
 
Description Takeda partnership with Gammadelta therapeutics 
Organisation Takeda Pharmaceutical Company
Country Japan 
Sector Private 
PI Contribution Spin out of GammaDelta
Collaborator Contribution KCL (in collaboration with the Crick and CRT) has formed a spin out company (GammaDelta Therapeutics). GammaDelta secured seed funding and liscensing deal with Abingworth LLP providing funding for 12-18 months of further research, allowing team to hire 2 more postdocs plus generous consumables. Gamma Delta T has now grown to 40 people. Takeda Pharmaceutical Company Limited and GammaDelta have just signed a strategic collaboration to to develop GammaDelta Therapeutics' novel T cell platform. Takeda, together with Abingworth, have committed up to $100 million in funding to accelerate GammaDelta Therapeutics led Research and Development. The funding includes an equity investment, an option fee and research and development funding, and provides Takeda the exclusive right to purchase GammaDelta Therapeutics. Under the agreement, Takeda will appoint a director to GammaDelta Therapeutics' board.
Impact NA
Start Year 2015
 
Description UK Thai collaboration 
Organisation Mahidol University
Department Siriraj Hospital
Country Thailand 
Sector Hospitals 
PI Contribution Over the past 6 months, I have begun to collaborate with that of Prof Pa-thai Yenchitsomanus in Bangkok in the area of CAR T-cell immunotherapy. My group has contributed know-how and plasmid reagents to support the development of novel CARs targeted against the MUC1 mucin and other solid tumour targets. I have also supported a fellowship application by one of the senior members of Prof Yenchitsomanus's group. In June, I visited the group of Prof Yenchitsomanus in Bangkok and have presented at two conferences there at which group members were also present. I look forward to hosting Prof Yenchitsomanus and a delegation from his group on a visit to London in October at which we will share research data and plan for further collaborations in this area.
Collaborator Contribution Prof Yenchitsomanus's group has offered us access to a human antibody library from which new CAR targeting moieties may be isolated. These plans are currently at an early stage and will be advanced following our next meeting in October.
Impact There have been no defined outputs as yet although the collaboration is at a very early stage.
Start Year 2016
 
Title EXPANSION OF NON-HAEMATOPOIETIC TISSUE-RESIDENT ? d T CELLS AND USES OF THESE CELLS 
Description The invention relates to a method for expanding non-haematopoietic tissue-resident ?d T cells ex vivo. The term "non-haematopoietic tissue-resident ?d T cells" refers to subsets of T lymphocytes that reside within non-haematopoietic tissues, rather than within lymphoid organs and blood. Such cells include non-Vd2 cells, e.g. Vd1, Vd3 and Vd5 cells. The invention also relates to the use of these cells in adoptive T cell therapy and in chimeric antigen receptor therapy, as well as their use in a method of screening for checkpoint modulators. The invention also relates to the cells produced as a result of ex vivo expansion of non-haematopoietic tissue-resident ?d T cells. 
IP Reference WO2017072367 
Protection Patent application published
Year Protection Granted 2016
Licensed Yes
Impact This patent application is co-owned by King's College London, Cancer Research Technologies and The Francis Crick Institute. It has been licensed to the London based Start-Up Company GammaDelta Therapeutics Ltd. of which King's College London is a founding Institution.
 
Title Therapeutic agents 
Description This patent describes a novel CAR platform known as a parallel CAR in which synergistic T-cell activating signals are delivered by two chimeric receptors with complementary endodomains. Exemplification is provided by a number of examples including pCARs targeted against CSF-1R, avb6 integrin and ErbB receptor tyrosine kinases. 
IP Reference WO2017021701 
Protection Patent application published
Year Protection Granted 2015
Licensed No
Impact PCT just published
 
Title avß6- binding peptides with variations in the RGD motif (+ fragments of these), avß6- binding peptides which are truncated versions of the 21-mer, HyCAR and HyPR constructs 
Description avß6- binding peptides with variations in the RGD motif (+ fragments of these), avß6- binding peptides which are truncated versions of the 21-mer, HyCAR and HyPR constructs 
IP Reference GB1701564.5, GB1702046.2, GB1701566.0, GB1702050.4, GB1701565.2, GB1702048.8, GB1701570.2, GB1702047.0 
Protection Patent application published
Year Protection Granted
Licensed Commercial In Confidence
Impact Spin out Leucid Bio raised circa 2.1M seed funding from Sofinnova and Epidarex
 
Company Name LEUCID BIO LTD 
Description Biotech company focussing on CAR (chimeric antigen receptor) technologies 
Year Established 2014 
Impact Leucid Bio raised circa £3.25m seed funding from Sofinnova and Epidarex.
 
Company Name GammaDelta Therapeutics Ltd. 
Description GammaDelta Therapeutics is focused on turning a breakthrough in the extraction and amplification of tissue-resident gamma-delta T cells into a pipeline of programs that can invade solid tumors more effectively than existing options. 
Year Established 2016 
Impact GammaDelta Therapeutics has received seed funding from the London based VC Abingworth and hast started its R&D program and translational work with a focus on GMP cell production. It currently employs 4 FTE scientists and is looking to increase this numbers to 12 by the end of 2017 whilst negotiating series A funding.
Website http://www.fiercebiotech.com/biotech/embargoed-until-19-01-edt-abingworth-seeds-i-o-startup-to-explo...
 
Description 7th biannual Gamma Delta T cell Conference, London 2016 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact We are organising the 7th international Gamma Delta T cell conference, taking place at King's College London in June 2016. We are expecting between 300-350 international participants including the leading experts in gamma delta T cell biology. The British Society of Immunology will feature the meeting prominently and Nature Immunology has announced to be present at the meeting. We are planning to present data funded by the MRC confidence in concept grant. One talk will focus on tissue resident human gamma delta T cells, their biology and cross talk with stromal cells, which has helped identify a possibly novel checkpoint inhibitor molecule controlling cytotoxic activity by gamma delta T cells. In the second talk, we will present our newly developed isolation and expansion method to grow tissue derived gamma delta T cells to large numbers ex vivo under optimised growth conditions, which was further developed with the help of MRC funding. Availability of gamma delta T cells for immunotherapy is novel and exciting and may open the door for further collaboration in the immunotherapy field and CAR T cell field.
Year(s) Of Engagement Activity 2016
URL http://www.gammadelta2016.uk
 
Description Academy of Medical Sciences and Association of Physicians 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact To bring together world class speakers and leading industry experts from across European Pharma, Biotech and Academic sectors to share, discuss, collaborate and innovate. Latest scientific breakthroughs, target validation studies, innovative technologies, and new therapeutics will be discussed.
Year(s) Of Engagement Activity 2017
 
Description Ada Lovelace 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Postgraduate students
Results and Impact This event is aimed at highlighting female scientists and their work as well as promoting discussion of gender equality in the sciences.
Ada Lovelace Day event featured talks from myself, Dr Maggie Aderin-Pocock, space scientist and presenter of The Sky at Night and Professor Paul Walton, of the Department of Chemistry at the University of York and long-time champion of equality in the sciences, will talk about gender equality issues in science. This was followed by a panel discussion about gender issues in science and academia and the event ended with a networking and poster session, at which PhD students presented their research.
Year(s) Of Engagement Activity 2015
URL http://www.kcl.ac.uk/nms/eventrecords/Ada-Lovelace-Day-2015.aspx
 
Description Appearance on BBC Radio 4, In Our Time programme on "Enzymes" 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact In Our Time is a live BBC radio discussion series exploring the history of ideas, presented by Melvyn Bragg since 15 October 1998. It is one of BBC Radio 4's most successful discussion programmes, acknowledged to have "transformed the landscape for serious ideas at peak listening time"
Melvyn Bragg and guests discuss enzymes, the proteins that control the speed of chemical reactions in organisms which would otherwise happen too slowly to keep the organisms alive.The purpose is to communicate a basic, fundamental but vital concept to teh general public.
The programme generated very positive reaction from the public on twitter.
Year(s) Of Engagement Activity 2017
URL http://www.bbc.co.uk/programmes/b08rp369
 
Description BM1305 COST meeting 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact A discussion on how the last grant period has been
Year(s) Of Engagement Activity 2017
 
Description Bench to bedside video 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Schools
Results and Impact The goal of this project was to educate students in the contributions that the individual sciences make to healthcare and health sciences. The project was institution wide and stemmed from a presetation I was previously involved with to a teachers conference on the same theme. In my segement I discuss chemistry in general but also the kinds of research we do and how it contributes to health sciences.
Year(s) Of Engagement Activity 2015
URL http://www.kcl.ac.uk/study/bench-to-bedside/chemistry.aspx
 
Description British Society of Histocompatibility and Immunogenetics (BSHI) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact Talks and discussions on new advances in both technology and therapy for transplantation
Year(s) Of Engagement Activity 2017
 
Description Cellular and Molecular mechanisms and new therapeutic concepts in translation 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact A 2 day symposium
Year(s) Of Engagement Activity 2017
 
Description Channel 5 interview 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Media (as a channel to the public)
Results and Impact Interview on Channel 5 about the Zika outbreak in Brazil
Year(s) Of Engagement Activity 2016
 
Description Children's Heart Charity Family Day Support (Essex) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Patients, carers and/or patient groups
Results and Impact Evelina Children's Heart Organisation held an annual family day. My role was to give a talk on our research, the impact it is having worldwide and how the families have been involved. We also ran an exhibition at this event. Over 200 people attended.
Year(s) Of Engagement Activity 2015
 
Description Diseases Plenary Session at ISCT 2017 London 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact so that the broad membership of ISCT can attend the Plenary Sessions for education in areas in which they are not experts and then attendees with specific interest in a field can attend the Plenary Breakout sessions which relate to their specific fields of interest for a more in depth presentation of the research. ISo that invited speakers have a greater opportunity to present their work in a single conference.
Year(s) Of Engagement Activity 2017
 
Description ESOT 2017 Barcelona 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact An educational experience to a broad audience with discussion
Year(s) Of Engagement Activity 2017
 
Description European Conference of Immunology, Vienna 2015 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact Accepted abstract at the European Conference of Immunology in the Category of Innate lymphocytes. The accepted poster described the research project, human tissue resident gamma delta T cell biology, their innate potential, the unidentified tissue checkpoint and their response to tissue disassociation. The poster was well received and generated discussion. One industrial representative asked for possible collaboration using laser induced delivery of molecules under sterile conditions within the human dermis in vitro. Dr. Mathias Eberl from the University of Cardiff suggested a collaboration on tissue resident gamma delta T cells and their role in TH2 skewing of CD4 Helper cells; this would complement published data on cytokine influences on gamma delta T cells very well, we are currently starting to phenotype and identify the specific subset of gamma delta T cells that are of interest to Dr. Eberl in order to confirm feasibility and POC of a possible collaboration. We further established a collaboration with the Kabelitz laboratory at the University of Kiel which will provide us with Hybridoma cell lines producing monoclonal antibodies against various human V gamma chains. Those antibodies are not commercially available and will help us to further describe tissue resident gamma delta T cells in diseased and healthy tissue sections. In general there was very positive feedback from a knowledgeable audience concerning the opportunities that may arise from our novel expansion method.
Year(s) Of Engagement Activity 2015
URL http://www.eci-vienna2015.org/images/docs/ECI2015_Abstract-Book-v2.pdf
 
Description Final ONE meeting 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact mmmmmm
Year(s) Of Engagement Activity 2017
 
Description GSTT MRes/PhD Programme in Biomedical and Translational Science Public engagement lecture series & MRC-DTP 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Policymakers/politicians
Results and Impact Our master's and PhD student cohort listened to individuals from the government select committee on science policy, publishers, biotech industry and clinical trial managers, public engagement experts from the charity sector and academia as well as public heath experts and an individual from the armed forces. The audience typically reached 50 individuals over six one hour sessions.
Year(s) Of Engagement Activity 2015,2016
 
Description Genetics Society Centenery Scientific Exhibiter at the 2019 Chelsea Flower Show 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact The Genetics Society Centenery Discovery Garden section at the Chelsea Flower Show, 2019. This will include a Mendel pea section. The Discovery Garden will be manned by academic geneticists to explain tothe general public about inheritance and genetic traits. In the past this forum has been impactful and this year will be measured by feedback surveys. Thousands of visitors pass through the week of Chelsea and I attend 3 of the 6 days.
Year(s) Of Engagement Activity 2019
URL https://www.rhs.org.uk/shows-events/rhs-chelsea-flower-show
 
Description Hosted 2 week visit from A-level student 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Schools
Results and Impact Hosted a student to shadow lab members for 2 weeks during the summer. This is part of the activities organised by the charity In2Science
Year(s) Of Engagement Activity 2016,2017
URL http://in2scienceuk.org
 
Description Immunotherapies in transplantation and cancer 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact A meeting focused on immunological mechanisms and treatments in transplantation and cancer that are common but have opposite final effects in each of these situations; a given tolerogenic mechanisms need to be fostered in transplantation and inhibited in cancer and viceversa.
Year(s) Of Engagement Activity 2012,2017
 
Description International Congress of Immunology, Melbourne 2016 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact We have submitted an abstract for oral presentation to the international Conference of Immunology in Melbourne in August 2016. Ever since the publication by Gentles et. al reporting their recent analysis (published in Nature Medicine) of 18,000 cancer patients (the largest such sampling ever to be undertaken) which revealed that a gamma delta T cell signature was the strongest positive prognostic indicator across 39 different tumour types, their is an immense interest in using human gamma delta T cells for adaptive immunotherapy or to identify specific ligands for their activation in situ. To our knowledge, because of their elusive numbers in human blood and the lack of extraction protocols from human tissue, we are the only lab capable of isolating, activating and expanding human tissue derived gamma delta T cells to large numbers. Furthermore we plan to report on their cytotoxic behaviour towards transformed cells which are partially mediated via NKG2D. We are optimistic that our request for an oral presentation will be accepted and that our findings will generate positive feedback with the field of basic immunology and applied immunotherapy.
Year(s) Of Engagement Activity 2016
URL http://ici2016.org/call-for-abstracts/
 
Description Interview for Newsnight 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Media (as a channel to the public)
Results and Impact interviews about COVID19 response
Year(s) Of Engagement Activity 2020
 
Description Lobby Event to raise politicians awareness of heart research funding (Westminster) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Policymakers/politicians
Results and Impact BHF event/ exhibition to lobby support in westminster for cardiovascular research
Year(s) Of Engagement Activity 2015
 
Description London Immunology Group and the British Society for Immunology 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Industry/Business
Results and Impact Annual Symposium with debate with panel of invited speakers.
Year(s) Of Engagement Activity 2017
 
Description Max Delbrück Centre for Molecular Medicine Careers Day Keynote invited speaker 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Postgraduate students
Results and Impact Max Delbrück Centre for Molecular Medicine Careers Day Keynote invited speaker
Year(s) Of Engagement Activity 2017
URL http://www.mdc-careerday.de/
 
Description NASMR 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Undergraduate students
Results and Impact Webcast for NASMR to highlight research intercalated BSc at KCL in immunobiology
Year(s) Of Engagement Activity 2016
 
Description NIHR BTRU in ODT 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Industry/Business
Results and Impact NIHR BTRU in Organ Donation and Transplantation
Year(s) Of Engagement Activity 2018
 
Description Participation in K+ Summer School event (KCL widening participation initiative) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Schools
Results and Impact K+ is a widening participation programme. it is a two-year programme of events, activities and academic workshops created to help support your university application and provide the skills students need to reach their potential as an undergraduate student. Students who successfully complete the programme are eligible for the K+ reduced offer to study at King's worth up to two A-level grades lower than the standard offer (excluding medicine and dentistry). Alongside this, all students who successfully complete the K+ programme will receive the K+ start up bursary of up to £1000 in their first year of university.K+ is run by King's College London.
As part of the summer programme I gave a talk to a group of students entitled "How and why do microbes make antibiotics?" and discussed where antibiotics come from and how and why bacteria use secondary metabolites as part of adaptation to their environmental niche. I also emphasised the importance of interdisciplinarity in modern scientific research. The event was online (due to covid).
Year(s) Of Engagement Activity 2020
URL https://kplus.london/
 
Description Pint of Science 2018 - Public engagement talk - "Where do drugs go inside your body?" by Dr Rafael T M. de Rosales 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact Public engagement talk for about 50 people
Year(s) Of Engagement Activity 2018
URL https://pintofscience.co.uk/event/molecular-surveillance-its-hot-stuff
 
Description Primary school talk / Burton on Trent - Science Week 2019 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Schools
Results and Impact Talk at primary school
Year(s) Of Engagement Activity 2019
 
Description Public engagement - Pint of Science 2017 - Dr Francis Man 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact Public engagement talk (Pint of Science) - Reprogramming immune cells to kill cancer
Year(s) Of Engagement Activity 2017
URL https://pintofscience.co.uk/event/when-chemistry--biology-collide
 
Description Public engagement with school children 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Schools
Results and Impact My team has participated in public engagement events in conjunction with the Institute for Research in Schools (IRIS), who work to give secondary school students the opportunity to become involved in real scientific research, and to expand their involvement in science beyond that of a textbook in a classroom. A-level students worked on a range of projects led by academics at local universities and presented their data at the Authentic Biology Symposium (funded by the Wellcome Trust) in November 2017. One of my PhD students (Laura Constable) was invited to speak at the symposium about inflammatory bowel disease and potential new therapeutic options in its treatment, with particular focus on cell therapy and how their immunomodulatory properties can be exploited to treat disease. In addition, she also participated in a panel discussion with students about becoming involved with scientific research (particularly about undertaking a PhD) and pursuing a career in science.
Year(s) Of Engagement Activity 2017
 
Description Realising Opportunities, academic skills module (Widening Participation Event) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Schools
Results and Impact Realising Opportunities (RO) is a unique collaboration of leading, research intensive universities, working together to promote fair access and social mobility of students from groups underrepresented in higher education.
This talk was part of their academic skills module. There were approximately 80 A level students attending this webinar (this would have course normally have been in person but due to Covid was converted to a webinar). The talk was entitled "How and why do microbes make antibiotics?" and discussed where antibiotics come from and how and why bacteria use secondary metabolites as part of adaptation to their environmental niche. I also emphasised the importance of interdisciplinarity in modern scientific research. Anonymous feedback indicated that it was received positively (see below). The Q and A was very lively indicating that students found the talk engaging.
K+ Academic Day student feedback:

1. The first lecture I watched was by Sarah Barry about Antibiotics which was very informative for me and fully captured me. It was my favourite lecture today especially learning about antibiotics resistance and how it affects us. I especially like the live event where we could ask questions and it was answered very detailed.

2. Dr.Barry made an interesting link between chemistry and biology and how both are used constantly for the benefit of medicine and new interventions. It reinforces the reasons we have to take both biology and chemistry at A-Levels. It was interesting.
Year(s) Of Engagement Activity 2020
URL http://www.realisingopportunities.ac.uk/
 
Description Regulation of the immune response in support of hematopoietic progenitor cell and solid organ transplantation 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Industry/Business
Results and Impact British Society for Immunology Congress
Year(s) Of Engagement Activity 2017
 
Description Therapeutic Tolerance Workshop 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact informal networking opportunity with discussion
Year(s) Of Engagement Activity 2017
 
Description UCB Seminar 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Industry/Business
Results and Impact Collaboration project
Year(s) Of Engagement Activity 2017
 
Description UK Humanised Mouse Symposium 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Industry/Business
Results and Impact A working group
Year(s) Of Engagement Activity 2018
 
Description UK Kidney Week 2017 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Industry/Business
Results and Impact an update on therapies in renal transplantation
Year(s) Of Engagement Activity 2017
 
Description UKRMP 2 Meeting 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Industry/Business
Results and Impact A working group
Year(s) Of Engagement Activity 2018
 
Description UKRMP NHSBT joint workshop 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Study participants or study members
Results and Impact forum to plan future strategy and collaborations in the field
Year(s) Of Engagement Activity 2017
 
Description Undergraduate lab visits/job shadowing 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Undergraduate students
Results and Impact 2 groups of 2 Chemistry undergraduates visited our laboratories to observe our research. They spent 2 days observing me undertaking pre-clinical scanning on this project and the premise of the research project was explained to them. The students were engaged and asked questions about the research and also about studying for a PhD and subsequent career paths. The students expressed an interest in going on to study for a PhD.
Year(s) Of Engagement Activity 2016